Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW231 multiple ascending dose and combination therapy in chronic hepatitis B (Phase Ib/II)
ChiCTR2600123516Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of LW231 in Chronic Hepatitis B (CHB) (4 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Phase Ib dose-limiting toxicity and safety profile and Phase II HBsAg change at week 24. Started Apr 2026; status: recruiting.
02
Drugs
LW231
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600123516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123516.